I would like to do my 2nd deep dive post #ASCO22 analysis on #ctDNA guided adjuvant therapy for pts with stage II colon cancer‼️
✳️The DYNAMIC trial is certainly step forward (kudos) ‼️But doesn’t answer many questions❗️@OncoAlert@manjuggm@CrcChange@TheColonClub Why ?👇
💊 Warfarin is standard of care for Antiphospholid Syndrome VTE prophlyaxis
💊 There is little evidence for DOAC use in this patient population
📃 This retrospective review assessed efficacy and safety of 50 low risk APL patients treated with apixaban or rivaroaxaban
@alex_epi_tria @AaronGoodman33 Can’t you argue those instances are due to ineffective abx / antifungals, I’m not sure if growth factor support would have changed outcome